1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in European Union, October 2019

Healthcare Analysis & Statistics in European Union, October 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • Firstword Pharma

All regions

data types

1-7 of 7 reports

Psoriasis: Update Bulletin [January 2018]

Psoriasis: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market. Topics covered include: Initiation of thePhase III BE VIVID trial for UCB’s bimekizumab (CDP-4940); ...

  • Industries : Pathology, Biotechnology
  • Countries : Europe, European Union
Cystic Fibrosis: Update Bulletin #3

Cystic Fibrosis: Update Bulletin #3

  • $ 1151
  • Industry report
  • December 2017

This edition presents world leading key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; expert opinions on Vertex Pharmaceuticals’ regulatory ...

  • Industries : Therapy
  • Countries : United States, Europe, World, European Union
Value Added Services in Cardiometabolic Diseases -- Payer views

Value Added Services in Cardiometabolic Diseases -- Payer views

  • $ 2537
  • Industry report
  • October 2017

Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post ...

  • Industries : Chronic Disease
  • Countries : United States, World, European Union
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

  • $ 1077
  • Industry report
  • January 2016

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : European Union, United States
Physician Views: Evaluating the launch of Novartis' Cosentyx for psoriasis

Physician Views: Evaluating the launch of Novartis' Cosentyx for psoriasis

  • $ 781
  • Industry report
  • June 2015

Approved in both the US and EU at the beginning of the year, Novartis' first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, European Union
Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

Physician Views: How do doctors see Praluent and Repatha stacking up after FDA panel meetings?

  • $ 634
  • Industry report
  • June 2015

The question of whether to approve Regeneron and Sanofi’s Praluent (alirocumab) and Amgen’s Repatha (evolocumab) never really seemed to be in doubt at FDA’s Endocrinologic and Metabolic Drugs Advisory ...

  • Industries : Therapy
  • Countries : United States, European Union
Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

  • $ 781
  • Industry report
  • January 2015

Novartis has become the first player to bring to market an interleukin-17A inhibitor, most recently announcing on Monday that the European Commission approved Cosentyx for the treatment of moderate-to-severe ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Europe, European Union


About 3600 reports

Download Unlimited Documents from Trusted Public Sources

Health Services Industry - Company Report, October 2019

  • October 2019
    8 pages
  • Hospital  

  • European Union  

View report >

CT Scan Industry in EU September 2019

EU Demographic Analysis September 2019


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on